Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed, Inc. (INSM) Form 4 shows Director Melvin Sharoky reported a sale of 10,000 shares of Insmed common stock on 08/20/2025 at a reported price of $129.50 per share. After the sale, the reporting person beneficially owns 274,516 shares, held directly and indirectly through various entities and UTMA custodial accounts.
The filing lists multiple indirect holdings: 100 shares held for Owen F. Paley UTMA/FL, 900 by Baby Gator LLC, 10,000 by Padonia, LLC, and additional amounts held for family members and custodial accounts. The report was signed by Melvin Sharoky via attorney-in-fact on 08/21/2025.
Insmed Inc. insider sale disclosure: The company's Chief Operating Officer, Roger Adsett, reported selling a total of 25,000 shares of Insmed common stock on 08/19/2025 in two transactions. The filings show 20,193 shares sold at a weighted-average price of $127.42 (range $127.00–$127.99) and 4,807 shares sold at a weighted-average price of $128.27 (range $128.00–$128.72). After these sales, the report lists beneficial ownership of 110,444 shares in one line and 105,637 shares in another line, each reported as direct ownership. The Form 4 was signed via power of attorney.
Insmed Inc. insider transactions by Chair and CEO William Lewis show option exercises and multiple stock sales executed under a 10b5-1 plan on 08/18/2025. The filing reports the exercise of 6,865 stock options at an exercise price of $10.85 and the acquisition of 6,865 common shares via that exercise. On the same date the reporting person sold a total of 6,865 common shares in separate sell transactions: 2,968 shares at a weighted average price of $127.59, 2,481 shares at $128.76, and 1,416 shares at $129.47. After these transactions the reporting person beneficially owns 303,911 shares indirectly and 50,500 shares indirectly via two trusts.
Insmed, Inc. (INSM) Form 144 filing reports a proposed sale of common stock by an insider. The notice shows 10,000 shares to be sold through Merrill Lynch (Orlando address) with an aggregate market value of $1,294,600.00 and company common shares outstanding listed as 211,374,786. The securities were acquired via stock options on 05/13/2021 (5,865 shares) and 05/22/2024 (13,192 shares). A sale of 10,000 shares by Melvin Sharoky on 08/12/2025 is also reported with gross proceeds of $1,215,350.00. The filer certifies no undisclosed material adverse information. Specific filing date is not provided in the content.
Insmed, Inc. (INSM) Form 144 notifies market participants that an insider intends to sell 25,000 shares of common stock through Merrill Lynch on 08/19/2025, with an aggregate market value of $3,188,795.00. The filing shows total outstanding shares of 211,374,786, indicating the proposed sale is a small fraction of the float. The shares to be sold were principally acquired through the company's stock plan between 2020 and 2025, with specific grant lots listed. The filer also reported two recent open-market sales in June 2025 totaling 12,546 shares for gross proceeds of $1,188,677.00. The notice contains the standard attestation that the seller is not aware of undisclosed material adverse information.
Insmed, Inc. (INSM) filed a Form 144 proposing the sale of 6,865 common shares under Rule 144, with an approximate aggregate market value of $881,244, to be sold through Merrill Lynch on NASDAQ on 08/18/2025. The filing states those shares were acquired on 08/18/2025 through stock plan activity and lists prior sales by the same account (William Lewis and William Lewis TTEE) totaling multiple transactions from 05/20/2025 through 08/04/2025, including a large sale of 129,805 shares on 06/16/2025 generating $13,027,678. The notice includes the standard Rule 144 attestation that the seller is not aware of undisclosed material adverse information.
Insmed insider stock sales totaling 10,000 shares were reported. The reporting person, identified as Chief People Strategy Officer and an officer/director, sold 3,554 shares at a weighted average around $126.57, 5,746 shares at a weighted average around $127.71, and 700 shares at a weighted average around $128.16, all on 08/14/2025. After these transactions the reporting person beneficially owned 79,764 shares.
The record shows specific price ranges for each block of shares sold and that 357 of the remaining shares were acquired through the company’s 2018 Employee Stock Purchase Plan. The filing includes a signed power of attorney for the submission. All details are reported on Form 4 and limited to these transactions and resulting ownership.
Insmed, Inc. insider filing on Form 144 notifies a proposed sale of 10,000 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $1,273,070. The filing lists the acquisition dates and amounts for 9 separate tranches received under the company stock plan between January 2022 and May 2023, totaling 8,820 shares disclosed in the acquisition table. The filer also reported recent open-market sales over the past three months: 99,172 shares on 06/11/2025, 38,300 shares on 06/10/2025, 1,642 on 06/03/2025, and 1,236 on 05/14/2025, producing gross proceeds of $12,853,585. The filer certifies no undisclosed material adverse information.
T. Rowe Price Associates, Inc. reports beneficial ownership of 11,230,934 shares of Insmed Inc. common stock, representing 5.9% of the class. The filing shows sole voting power over 10,918,453 shares and sole dispositive power over 11,188,173 shares, with no shared voting or dispositive powers. The firm states these shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure identifies T. Rowe Price as an investment adviser and clarifies there is no group affiliation noted. This is a material institutional ownership disclosure but does not, by itself, indicate an intent to exert control.
Insmed, Inc. (INSM) reported a Form 144 notice showing an insider intends to sell 13,600 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,654,338.00 and an approximate sale date of 08/13/2025. The shares were acquired in two restricted-stock vesting events: 5,942 shares on 05/15/2019 and 7,658 shares on 05/12/2021, both listed as consideration for services rendered. The filing also discloses a prior sale by the same person of 25,000 shares on 06/10/2025 for gross proceeds of $2,180,846.00.
The notice states the filer represents they have no undisclosed material adverse information about the issuer. Outstanding shares are shown as 211,374,786, which provides context for the scale of these transactions versus total shares outstanding.